Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01678625 · ClinicalTrials.gov registry record
Electromyographic Assessment of Onset and Recovery of Neuromuscular Blockade
A clinical trial, sponsored by Endeavor Health.
- Terminated
- Registry status
- 30
- Enrollment target
NCT01678625 is a clinical trial that was terminated before completion, run by Endeavor Health. The registered enrollment target is 30 participants.
The verdict
NCT01678625 was terminated before completion, sponsored by Endeavor Health.
- TERMINATED
- Registry status
- 30 participants
- Enrollment target
Study Summary
Residual neuromuscular blockade (weakness) is a common occurrence in the postanesthesia care unit when muscle relaxant drugs have been used in the operating room. The only method of reliably detecting the presence of neuromuscular blockade is through the use of quantitative neuromuscular monitors. These devices measure and quantify the degree of muscle weakness and display the results on a screen. When using train-of-four (TOF) nerve stimulation, the ratio of the fourth muscle contraction (twitch) to the first twitch will be displayed; when this ratio is 90% (or 0.9) or greater, full recovery of muscle strength is present, and the endotracheal tube can be removed. At the present time, there is only one commercially-available quantitative monitor available in the United States -the TOF-Watch. It is not used by many clinicians because it requires experience to obtain accurate results, is expensive, and is subject to interference by factors in the operating room. The aim of this investigation is to examine a new quantitative monitor (the T4-EMG (EMG = electromyography) that may not be subject to the same limitations as the TOF-Watch AMG (AMG = acceleromyography). In order to study the accuracy of this new device, the T4-EMG will be compared to the current "clinical gold standard", the TOF-Watch.
Interventions
- DEVICE Train-of-four ratio calculation (T4-EMG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-06 |
| Est. Completion | 2013-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01678625
The ClinicalTrials.gov registry entry for NCT01678625 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endeavor Health, which has 94 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Train-of-four ratio calculation (T4-EMG) is the first listed.
NCT01678625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01678625 about?
NCT01678625 is a clinical study titled "Electromyographic Assessment of Onset and Recovery of Neuromuscular Blockade". Residual neuromuscular blockade (weakness) is a common occurrence in the postanesthesia care unit when muscle relaxant drugs have been used in the operating room. The only method of reliably detecting the presence of neuromuscular blockade is through the use of quantitative neuromuscular monitors. T...
What is the current status of trial NCT01678625?
This trial is currently terminated. The enrollment target is 30 participants. The study started on 2012-06. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01678625?
The interventions under investigation include: Train-of-four ratio calculation (T4-EMG) (DEVICE).
Who is sponsoring clinical trial NCT01678625?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.